Macau Casino Gambli...
Health Care: Drugs
Cellceutix Corporation (CTIX: OTC)
$0.57 0.02 | 3.64%
06/01/12 - 03:58 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.96 | 0.58 | 0.98 |
| Price to Sales (TTM) | 0.00 | 4.62 | 1.42 |
| Price to Book (MRQ) | 0.00 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | -7.11 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -11.50 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -74.60 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | n.a. | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 0.00 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 0.00 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | n.a. | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | n.a. | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | n.a. | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -4,589.00 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | n.a. | 2.20 | 2.50 |
| Return on Investment (TTM) | 62.70 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | 82.60 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 0.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -230,025.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with CTIX
- Portfolio NameUser Type
Latest CTIX Headlines from TheStreet
- Cheap Tickets Up as Cendant Extends Share Offer Deadline 09.24.01 | 08:09 am
- Cheap Tickets Tumbles on Warning 06.26.01 | 11:06 am
- The Daily Interview: Online Travel Skies Getting Crowded 06.13.01 | 10:06 am
- Ticker-Tape Parade: Cendant Buys Cheap Tickets, Semis Get an Upgrade 12.31.69 | 07:12 pm
- Cheap Tickets Leaps on Offer From Cendant 12.31.69 | 07:12 pm
Press Releases for CTIX
- Cellceutix CEO, Leo Ehrlich, Conducts Interview With "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board - PR Newswire 04.18.11 | 07:04 am
- Cellceutix Poster Presentation On Its P53 Cancer Breakthrough Attracts Wide Interest At 102nd AACR Meeting - PR Newswire 04.11.11 | 06:04 am
- Cellceutix Cancer Drug, Kevetrinâ¢, Shows Increased Levels Of P21; Biomarker For Cancer Trials - PR Newswire 03.31.11 | 08:03 am
- Cellceutix Announces That It Has Signed Confidential Disclosure Agreement For Its Autism Drug With Large Pharmaceutical Company - PR Newswire 03.28.11 | 07:03 am
- Cellceutix Anti-Cancer Breakthrough Selected For Poster Presentation At American Association For Cancer Research (AACR) - PR Newswire 03.21.11 | 07:03 am
- Cellceutix Reports Production Of Its Anti-Cancer Drug Kevetrin⢠Has Begun - PR Newswire 03.14.11 | 06:03 am
- Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company - PR Newswire 03.08.11 | 04:03 pm
- Cellceutix Discovers Drug Activates 'Guardian Angel P53' In Fight Against Leukemia - PR Newswire 03.07.11 | 07:03 am
- Cellceutix Cancer Drug Kevetrin⢠Shows No Genotoxicity In Study - PR Newswire 03.02.11 | 07:03 am
Partner Headlines for CTIX
